EODData

MEMBERSHIP REGISTER LOG IN

FRA, C43: Cosmo Pharmaceuticals N.V

21 Jan 2026
LAST:

123.0

CHANGE:
 4.00		OPEN:
123.0		HIGH:
125.0		ASK:
0.0		VOLUME:
178
CHG(%):
3.36		PREV:
119.0		LOW:
122.0		BID:
0.0		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
21 Jan 26123.0125.0122.0123.0178
20 Jan 26119.0119.0119.0119.08
19 Jan 26119.0119.0119.0119.0200
16 Jan 26115.0120.0115.0120.0200
15 Jan 26114.0117.0114.0116.0300
14 Jan 26112.0114.0112.0114.0101
13 Jan 26115.0115.0111.0111.0624
12 Jan 26116.0116.0116.0116.049
09 Jan 26118.0118.0116.0116.0190
08 Jan 26117.0118.0117.0118.0131

PROFILE

Name:Cosmo Pharmaceuticals N.V
About:Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with a faster and less risky excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Relafalk, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers' diarrhoea; and Byfavo, an intravenous benzodiazepine sedative/anesthetic. It is also developing Breezula, a novel androgen receptor inhibitor, which is in Phase III trials and targets androgen receptors in the scalp; Rifamycin 1% enema that is in Phase II clinical trial for the treatment of distal ulcerative colitis and proctitis; Colesevelam, which is in preclinical studies for the treatment of bile acid diarrhea; and Cortexolone 17a-valerate-21-propionate, an oral Androgen receptor and glucocorticoid receptor antagonist that is in Phase I clinical trial for treatment solid tumors, as well as provides Cosmo's AI technology, a GI Genius intelligent endoscopy system. The company has development, distribution, and licensing agreements with Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, RedHill Biopharma Ltd., Sun Pharmaceutical Industries Ltd., 3SBio, InfectoPharm, and Hyphens Pharma International Limited. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
Sector:Healthcare
Address:Riverside II, Dublin, Ireland, 2
Website:https://www.cosmopharma.com
ISIN:NL0011832936
LEI:724500OX0EBQRYTVV639

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:31.93 
Forward P/E:12.05 
Price to Sales:10.06 
Price to Book:3.95 
Profit Margin:0.33 
Operating Margin:-0.03 
Return on Assets:0.07 
Return on Equity:0.12 
DivYield:0.03 
Div/Share:2.05 
Revenue:182.27M 
EBITDA:169.82M 
Shares:15.94M 
Market Cap:1.96B 

TECHNICAL INDICATORS

MA5:119.403.0%
MA10:117.204.9%
MA20:114.907.0%
MA50:94.1930.6%
MA100:82.0849.9%
MA200:70.4774.6%
STO9:85.71 
STO14:85.71 
RSI14:67.86 
MTM14:9.00
ROC14:0.08 
ATR:2.50 
Week High:125.001.6%
Week Low:112.009.8%
Month High:125.001.6%
Month Low:107.0074.6%
Year High:125.001.6%
Year Low:47.73157.7%

RECENT DIVIDENDS

Date Amount
04 Jun 2025$2.05
10 Jul 2024$2.00
28 May 2024$2.00
31 May 2023$1.05
01 Jun 2022$0.95
31 May 2022$0.95
29 May 2017$1.50
30 Aug 2016$1.40
17 May 2016$1.40